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Simple Summary: Stage of the disease at diagnosis has been recognized as one of the most important
prognostic markers for oral cancer. Unfortunately, still two thirds of patients are diagnosed at an
advanced stage of disease with a 5-year survival rate of 50% or less. Although the detection of oral
cancer at an early stage is the most effective means to improve survival and reduce morbidity, in the
past years, there has been little change in the diagnosis of oral cancer at early stages, which is believed
to be a result of delays in diagnosis and treatment of oral cancer, among other independent factors.
Following the Aarhus statement, developed in effort to standardize the design, methods and reporting
of studies concerning time-intervals in early diagnosis research, the review assessed the causes that
influence the patient, diagnosis and pre-treatment intervals in the pathway of time-to-treatment in
oral cancer and its impact on survival.
Abstract: The purpose of this review was to identify and describe the causes that influence the
time-intervals in the pathway of diagnosis and treatment of oral cancer and to assess its impact on
prognosis and survival. The review was structured according to the recommendations of the Aarhus
statement, considering original data from individual studies and systematic reviews that reported
outcomes related to the patient, diagnostic and pre-treatment intervals. The patient interval is the
major contributor to the total time-interval. Unawareness of signs and/or symptoms, denial and
lack of knowledge about oral cancer are the major contributors to the process of seeking medical
attention. The diagnostic interval is influenced by tumor factors, delays in referral due to higher
number of consultations and previous treatment with different medicines or dental procedures and
by professional factors such as experience and lack of knowledge related to the disease and diagnostic
procedures. Patients with advanced stage disease, primary treatment with radiotherapy, treatment at
an academic facility and transitions in care are associated with prolonged pre-treatment intervals. An
emerging body of evidence supports the impact of prolonged pre-treatment and treatment intervals
with poorer survival from oral cancer.
Keywords: head and neck cancer; oral cancer; time-to-treatment; treatment delays; early diagnosis;
survival rate
1. Introduction
In 2018 oral cancer accounted for 354,864 (2%) new cases and 177,384 (1.9%) deaths
worldwide, with the highest incidence in Southern Asia and the Pacific Islands and being
the eighth most common type of cancer in men [1]. Despite advances in diagnosis and
oncologic treatment during the last decades, the 5-year survival rates of oral cancer still
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remain in the 50–60% range [2,3], with a slight increase observed in the United States (US)
during the last decade (66%) [4].
Several factors have been assessed as independent prognostic factors for head and
neck cancer (HNC). These factors include demographic and patient factors, lifestyle factors,
treatment modality factors and tumor factors [5]. However, of the prognostic factors, tumor
size and increased stage, nodal involvement (extracapsular spread), distant metastasis,
positive margins and, consequently, the stage of the presenting lesion at diagnosis are the
most important prognostic markers for oral cancer [2,5,6]. Unfortunately, still two thirds
of patients with oral cancer are diagnosed at an advanced stage of disease (stage III and
IV) [3,7] with a 5-year survival rate of 50% or less [2] compared to the more than 80%
survival rate in those with localized disease, which make the differences in mortality rates
based on staging very marked [8].
The detection of oral cancer at an early stage is the most effective means to improve
survival and, at the same time, reduce morbidity, disfigurement, duration of treatment
and hospital costs. It may also enhance psychological outcomes and quality of life [9,10].
However, according to the National Cancer Institute’s SEER program, in the past 10 years,
only 28.7% of oral cavity and pharynx cancers were diagnosed at a local stage (stage
I) [4], which is believed to be a result of the silent nature of early oral lesions and delay in
diagnosis [11].
To date, there are no standardized definitions for describing delays in diagnosis
and/or treatment of oral cancer, with diverse definitions existing among the literature to
describe the patient’s pathway from their first awareness of symptoms to the initiation
of treatment [12]. Moreover, the absence of a theoretical framework and the lack of a
consensus on a time-point beyond which a cancer diagnosis should be considered as
delayed [13] has led to the use of a wide range of endpoints for defining “delay” in research
which is mostly based in arbitrary cut-off points.
In effort to standardize the design, methods and reporting of studies concerning
time points and intervals in early-diagnosis research, the Aarhus statement has been
proposed [14]. This guideline is a refined version derived from the Andersen Model of
Total Patient Delay [15] which also recommends the replacement of the term “delay” for
“time-intervals” as the former term is considered value laden and inaccurate [15]. The
statement suggests the use of four key time points (date of first symptom, date of first
presentation, date of referral and date of diagnosis) and their associated time-intervals,
appraisal, help-seeking, diagnostic and pre-treatment intervals [14] to describe the patients
pathway from first symptom awareness to the initiation of treatment, considering that all
the process take place within a health system that can influence the length of time-intervals
and so will have effects on all stages of this pathway [16]. Cultural and social determinants
of health must also be taken into account as they also have an impact on all aspects of the
length-time in treatment of oral cancer (Figure 1).
It has been reported that the mean total-interval, defined as the time between the
patient first awareness of signs and/or symptoms until the initiation of treatment, is
206 days with a range of 52–786 days (~6.9 months) [17]. Consistently, a recent systematic
review reported a mean total-interval of 186.7 days (~6.2 months), derived from data of
four studies reporting on 527 patients [18].
Following the Aarhus statement, the purpose of this review is to identify and describe
the causes that influence the length-time in treatment of oral cancer and assess its impact
on prognosis and survival. For practical considerations, the appraisal and help-seeking in-
tervals were reported in one interval, the patient interval, as many studies report outcomes
for the time-interval between the patient first awareness of signs and/or symptoms and
his first consultation to a healthcare provider.




Appraisal interval Help-seeking interval 
Diagnostic interval 
Healthcare system 
Cultural and social determinants of health 
~1 month 
Tumor factors 




Figure 1. Time-intervals in the pathway of diagnosis and treatment of oral cancer.
2. Patient Interval
The patient interval is defined as the time between the patient first awareness of
signs and/or symptoms and his first consultation to a healthcare provider (HCP) and com-
prises both the appraisal and help-seeking intervals [14,18]. It is reported to be the most
significant contributor to the total time-interval [2,12,17], comprising 1.6 to 5.6 months ap-
proximately [7,12,19,20]. Peacock et al. [17] reported a mean patient interval of 3.5 months
(104.7 days) in the US and similar results were described in a study conducted in German
patients with HNC, where the time elapsed between the first symptoms and medical consul-
tation for the majority of patients (63.5%) was 3–4 months [21]. On the other hand, results
from a study conducted in Chinese patients with oral cancer reported a median patient
interval of 1 month (30 days) [22] and similar results were reported in Iranian patients with
a median interval of 1.5 months (45 days) [23]. The results from the systematic review pub-
lished by Varela-Centelles et al. [18] described a weighted mean of 80.3 days (~2.7 months)
calculated from 2151 patients, with the shortest intervals (28–42 days) reported from Europe
(The Netherlands, Finland).
Causes Influencing the Patient Interval
Studies evaluating sociodemographic variables such as age, gender, area of residence or
religion have consistently shown a non-association with the patient interval [10,11,24]. It has
also been reported that the patient interval is independent of health-related behaviors, i.e.,
tobacco and alcohol consumption [10,11,19] and of clinical/tumor factors [9,11]. Rather, the
patient interval seems to be mainly related to cognitive and psychosocial variables [24]. Un-
awareness of signs and/or symptoms, nonpersonal experience of cancer, lack of knowledge
about cancer and denial have been assessed as strongly independent factors associated to
the patient interval [24].
Research on other diseases indicates that symptom appraisal is the most important
stage in the process of seeking medical attention, constituting approximately 60% of the
total route [9], being the non-recognition or misinterpretation of symptoms, mainly to
the lack of knowledge [25], the most predominant risk factor [24]. A qualitative study
reported that patients often attributed their symptoms to transient, minor conditions (i.e.,
mouth ulcer, physical trauma, dental problems) and, in turn, were unconcerned about
their presence [26]. Hence, patient’s cognitive and emotional perceptions are determining
factors in their decision to seek or not to seek help. The least common initial interpretation
was cancer which may reflect the general lack of knowledge of the disease that may lead
to misguided appraisal of their symptoms and thus can lead to inappropriate behavioral
responses which may adversely affect help-seeking behavior [9,26]. In that context, Scott
et al. [11] showed that knowledge of oral cancer in the UK was independently associated
with the patient interval, indicating that participants who had more accurate knowledge of
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oral cancer were less likely to delay seeking help (OR: 0.75, 95%CI 0.57–0.98). Similarly,
Zhang et al. [22] reported that patients in China with higher oral cancer knowledge had a
lower possibility of delay in seeking professional advice, although not statistically signifi-
cant (OR: 0.88, 95%CI 0.60–2.01). Reda et al. [27,28] demonstrated that a low health literacy
was associated with a lower utilization of dental services, an indicator of healthcare access,
(OR: 0.41, 95%CI 0.01–0.81) [28] and that participants with lower educational level had
a significantly lower access to dental services compared to those with higher education
level (OR: 0.61, 95%CI 0.55–0.68) [27]. Health literacy is closely related with oral health
beneficial behavior and is associated with general education [28], thus conditioning the
decision to seek medical attention which could also be influenced by educational barriers.
Moreover, there are large differences in access and utilization of dental services accord-
ing to different social, demographic, economical or educational factors that can influence
the prevention, diagnosis and management of oral diseases. It has been identified that
access to dental services is lower in ethnic minorities or immigrants, in those living in
rural places, those with lower educational and income level and among those without
insurance coverage which reflects inequalities in access to dental care [27]. Scott et al. [29]
also recognized problems with access to an HCP in the UK, which included the distance
needed to travel and the cost of a consultation which were perceived as barriers for seeking
medical attention. This population should also be targeted as a high-risk group, as their
social, structural, demographical and economical barriers can decisively condition their
timing of oral cancer diagnosis [30].
3. Diagnostic Interval
The diagnostic interval is defined as the time from first consultation by an HCP to
achieving the definitive diagnosis [14,18] and it is where patients with asymptomatic
lesions that are potentially able to be detected through opportunistic screening would enter
the model’s pathway [31].
Length-time of diagnostic interval vary substantially across studies. Friedrich et al. [21]
reported a mean diagnostic interval of 7.1 months in Germany, while Yu et al. [20] reported
a median time-interval of 3 months in Canada, finding that initial treatment by general
practitioners (GP) before referring to a specialist was associated with a higher diagnostic
interval. In patients with newly diagnosed HNC, a median diagnostic interval of 14 days
was reported by two studies in Europe [32,33], although one of them did not consider the
time from first consultation by an HCP to the first visit to a specialized professional [32].
The pooled estimate of the aforementioned systematic review [18], comprising a total of
1324 patients with symptomatic oral lesions, reported a diagnostic interval of 48 days
(~1.6 months). The authors identified that the longest intervals were reported in the US
in the 1980s and more recently in Australia and Iran. On the other hand, the shortest
diagnostic intervals (21–22 days) were reported from European countries [18].
Causes Influencing the Diagnostic Interval
It has been reported that diagnostic interval is related with tumor factors such as stage
at presentation and localization of the tumor with small tumors (T1–T2) and laryngeal
tumors associated with a higher time-interval in diagnosis [32]. An explanation could be
that diagnosis is easier when tumors are larger because they are visible and because the
oral cavity is easily accessible for examination [32]. Other factors associated are a higher
number of consultations (≥3) before achieving definitive diagnosis, previous treatment
with different medicines (analgesics, antibiotics) and previous dental procedures [23]. The
results of a previous systematic review reported that dentists were more likely to delay
referral when compared to GP as they can first undertake dental procedures; still there
was no clear difference in stage of the disease at diagnosis or delay in referral between the
professionals [8].
Other causes related are low index of suspicion, lack of familiarity and experience with
the disease and lack of oral cancer knowledge on diagnostic procedures, main locations of
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oral cancer and leuko- or erythroplakia-like carcinomas as primary oral cancer lesions [30].
Early diagnosis of oral pre-cancerous lesions is particularly challenging because it requires
practitioners to be familiar with the range of clinical presentations of potentially malignant
disorders, many of which may resemble less serious conditions [31]. In addition, dental
and GP may not easily discriminate malignant lesions due to the low incidence of oral
malignancies among the general population and the nonspecific appearance of the lesions,
especially in young and low risk patients [7]. A recent systematic review stated that there
was a low level of awareness among medical practitioners regarding common potential
malignant oral lesions involving leukoplakia (56%), erythroplakia (30%) and oral lichen
planus (13%) and a moderate knowledge about frequent sites of oral cancer development
involving the tongue (48%) and floor of the mouth (37%). Moreover, only 27% of medical
practitioners performed an intraoral examination as a routine [34]. This point to the key
importance of recognition of abnormality; as without this, no further action would be
taken [7].
Additionally, definitive diagnosis depends on diagnostic procedures such as detection
of tissue change, decision to biopsy, biopsy site selection, quality of the tissue submitted,
laboratory procedure and pathologist’s skill and interpretation. Consequently, each step-in
patient presentation and professional decision making can contribute to increase the diag-
nostic time-interval [7]. Regarding the decision to biopsy, results from a study conducted in
121 Brazilian dentists showed that only 10.7% of the professionals routinely would perform
biopsies and only 3.3% would perform in any situation (independent on the complex-
ity) [35]. Anandani et al. [36] reported that 50.8% of dentists in India preferred to refer the
patients to a specialist to perform the biopsy being the reasons for their reluctance the lack
of instruments and experience required for taking biopsies. Also, 46.3% of the dentists sent
the tissue for analysis only when suspecting premalignancy [36]. Results from a Spanish
study indicated that 50% of dentists performed at least one biopsy per year to confirm or
rule out oral cancer. Furthermore, the diagnostic sensitivity for oral cancer was 61.4% and
57.8% for the combined oral cancer and premalignant oral lesions [37]. Therefore, poor
knowledge and confidence of practitioners in screening, biopsy and referral of suspicious
lesions appear to be significant, but modifiable, negative influences in the early detection
and diagnosis of oral cancer [31].
4. Pre-Treatment Interval
The pre-treatment interval is defined as the time from the diagnosis to the start of treat-
ment [14] and may be influenced by the patient, the health system and lesion factors [15,31].
Results from a study conducted in the United States (US), that used the National Cancer
Data Base, reported a median pre-treatment interval of 30 days [38]. Similarly, Kaing
et al. [39] reported a median time from diagnosis to definitive treatment of 30 days (range
0–9 weeks) in 101 Australian patients firstly diagnosed with OSCC and Lyhne et al. [33]
a median time-interval of 25 days in Denmark. The results provided showed a signifi-
cant reduction in pre-treatment waiting time for HNC patients of 41% from 2002 to 2010,
corresponding to a reduction of four weeks with the most pronounced reduction seen in
waiting time for definitive radiotherapy that decreased 3 weeks [33]. The authors con-
cluded that the implementation of a fast-track policy in Denmark in 2007 could be an
important contributing factor for the decrease [33]. Contrary, in the US an increase of 58%
in the pre-treatment interval was found between 1998 (19 days) and 2011 (30 days) with an
overall median of 26 days [40]. The authors discussed that the trend in rising could possibly
be due to increases in sophistication and number of pre-treatment radiologic/pathologic
testing, increases in the use and complexity of multimodality therapies and increased
transitions in care [40].
Causes Influencing the Pre-Treatment Interval
Patient factors associated with an increased pre-treatment interval are age ≥60 years
and concurrent comorbidity [38,41]. The presence of comorbidities may require optimiza-
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tion before initiation of surgical or medical oncologic therapy which may lengthen the
diagnosis-to-treatment time [41]. Treatment at an academic/research facility (educational
institutions) and diagnosis at an outside facility has also been associated with an increase
pre-treatment interval [38]. In that context, Murphy et al. [40] reported that treatment at
an academic facility in the US was associated with a higher time-interval in treatment
initiation (median = 35 days) compared to treatment at a community facility (median =
28 days) and transitions in care, defined as a change in facility from diagnosis to definitive
treatment, was also associated with a significantly longer median pre-treatment interval.
Similarly, van Harten et al. [42] described a longer pre-treatment interval in patients in The
Netherlands who experienced transitions in care (median = 44 days) compared to those
diagnosed and treated in the same center (median = 31 days), probably attributed to a delay
in referral. Other factors significantly associated with a prolonged pre-treatment interval
were African American race, Hispanic ethnicity, lack of insurance or Medicaid coverage,
lower education levels and distance of primary residence from treatment facility [40,43], all
of which reflect the barriers and difficulties of social determinants of health in the initial
access to healthcare.
Patients with advanced stage disease has also been significantly associated with a
longer pre-treatment interval [40–42]. Significant differences have also been reported be-
tween treatment modalities, were patients treated with primary radiotherapy or chemoradi-
ation experienced a longer diagnosis-to-treatment interval (median = 57 days [41], median
= 42 days [42]) compared to patients surgically treated (median = 30 days [41], median =
30 days [42]). Patients at an advanced stage disease require a multidisciplinary treatment
approach with the involvement of multiple subspeciality physicians and oncologic special-
ists before initiation of treatment as well as the frequent need of dental visits for assessment
of oral health status and dental extractions for improvement of their oral health condition
before treatment or radiotherapy initiation, therefore, lengthening the time-to-treatment
initiation [41].
Finally, institution-based factors affecting timely delivery of oncologic care include
availability of specialty service, outpatient clinic appointments, adequacy of outpatient
clinic equipment, timely pathologic analysis of biopsy specimens, availability of outpatient
treatment scanning and operating room access [41]. In that context, Peacock et al. [17]
reported a mean time from completion of tests to case presentation to the head and neck
tumor board of 20.7 days (range: 1–208 days) in the US and a mean time from case pre-
sentation to the board to initiation of definitive treatment of 18.6 days (range: 1–76 days)
attributing the delays in obtaining insurance authorization and in scheduling an operat-
ing room.
5. Implications on Prognosis and Survival
Prolonged length-time in treatment of oral cancer may impact survival as during this
time-interval the tumor has the capability to increase in size and metastasize compromising
the patient’s prognosis. Kowalski et al. [44] revealed the potential clinical upstaging of
HNC in Brazil before initiation of treatment and demonstrated that the median 5-year
survival rate of patients with clinical upstaging before treatment was significantly poorer
(17.2 months) than patients without clinical upstaging and who received treatment within
a short period of time (1–3 weeks) (32.7 months) [44]. Likewise, Xiao et al. [45] determined
that increasing time-to-treatment initiation (TTI) in the US was significantly associated with
clinical upstaging, suggesting tumor progression. Also, upstaged patients had a poorer OS
compared to patients who were not upstaged (5.07 vs. 7.10 years, respectively, p < 0.001).
When adjusting by upstaging, TTI was only a significant predictor of increased mortality
beyond ≥70 days indicating that TTI itself is not a consistent predictor of mortality and
is not independent of tumor progression [45]. The results suggest that survival from oral
cancer depends more by the proliferative activity of the tumor (tumor progression) than by
a prolonged time-interval to diagnosis [46].
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Several systematic reviews have assessed the impact of time-to-treatment in HNC on
OS (Table 1). The results from Graboyes et al. [47] provided support that starting postoper-
ative radiotherapy within 6 weeks or less of surgery is associated with improved OS. Also,
from the 13 included studies, nine reported a significant association between a prolonged
pre-treatment interval and poorer OS, although there was a high heterogeneity among the
studies regarding definitions and thresholds used for defining the diagnosis-to-treatment
interval. The systematic review published by Seoane et al. [48] which included 10 studies,
showed that a prolonged interval to diagnosis was associated with a moderate risk of
mortality from HNC (“any delay” = RR: 1.34, 95%CI 1.12–1.61). The patient and diagnostic
intervals were associated with an increased risk mortality but were not statistically signifi-
cant. Only referral delay was associated with a three-fold increased mortality rate, although
this pooled estimate was based on only two studies. Nonetheless, these results must be
interpreted with caution as included studies were highly heterogeneous regarding tumor
location, assessment and thresholds used for defining “delay” and some studies lacked
to control for known confounding factors that may influenced the associations observed.
Later, Seoane et al. [49] conducted a systematic review focused on patients diagnosed with
OSCC reporting similar results as the previously published [44]. They also found that both
prolonged patient interval and diagnostic interval were associated with a more advanced
stage of disease (III or IV) at diagnosis with a higher effect size for the diagnostic interval
(OR: 2.15, 95%CI 1.08–4.29) than for the patient interval (OR: 1.55, 95%CI 1.14–2.12) [49].
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Meta-analyses for TNM
Any delay (seven studies): OR = 1.66 (1.25–2.20)
Patient delay (four studies): OR = 1.55 (1.14–2.12)

















Any delay (10 studies): RR = 1.34 (1.12–1.61)
PD (Five studies): RR = 1.67 (0.88–3.19)
PDI (Five studies): RR = 1.32 (0.66–2.66)
RD (two studies): RR = 3.17 (1.12–9.00)
Total DD (two studies): RR = 1.04 (1.01–1.07)
Abbreviations: SCC = Squamous cell carcinoma; DTI = Diagnosis to treatment initiation; S-PORT = Surgery to postoperative radiotherapy
initiation; TPT = Treatment package time (surgery to completion of postoperative radiotherapy); OS = Overall survival; HR = Hazard
Ratio; DI = Diagnostic interval (time-interval between first symptomatic presentation and patient referral, or histological diagnosis or
start to treatment); HNC = Head and neck cancer; PD = Patient delay (time from the patient’s first awareness of symptom/sign to the
first consultation with a physician or dentist); PDI = Presentation-to-diagnosis interval (time from the patient’s first consultation with a
physician or a dentist to the date of histological diagnosis); DD = Diagnostic delay (the sum of the patient and professional delay); RD =
Referral delay (difference between the date of first symptom and the date of the referral letter transferring the patient to the secondary
care level).
Recent research has focused on estimate the impact of the pre-treatment interval on
OS from HNC, with findings differing across the literature (Table 2). On the one hand,
Tsai et al. [50] showed that patients in Taiwan treated after 30 days from diagnosis had a
Cancers 2021, 13, 1321 8 of 13
lower OS rate from oral cancer when compared to those treated within 30 days; the trend
observed remained the same after stratifying by initial tumor stage at diagnosis. Similarly,
a prolonged pre-treatment interval (>30 days) was associated with worse OS in patients
with stage III or IV oropharyngeal squamous cell carcinoma (HR: 1.12, 95%CI 1.03–1.20)
and with a 2.2% (95% CI, 1.1–3.3%) increased risk of death for every 1 week increase in the
diagnosis-to-treatment interval [43].
Table 2. Studies assessing the impact of pre-treatment and treatment intervals on survival from head and neck cancer.
Author/Country/












>120 days (n = 572): HR = 1.32 (1.19–1.47)
31–120 days (n = 2498): HR = 1.18 (1.11–1.25)






diagnosed with stage III




>30 days: HR = 1.12 (1.03–1.20)
≤30 days: Reference
>6 weeks: HR = 1.22 (1.10–1.35)
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>30 days: HR = 1.00 (0.94–1.07)
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Continuously (days): the hazard of dying
ascends sharply to 25 days, then the curve












≥91 days: HR = 1.23 (1.15–1.32)
61–90 days: HR = 1.08 (1.03–1.13)


















≥45 days: HR = 0.98 (0.88–1.09)
≤30 days: Reference
SRTI
≥64 days: HR = 0.96 (0.81–1.15)
≤50 days: Reference
RTI
≥54 days: HR = 1.22 (1.03–1.44)
≤49 days: Reference
TTP
≥116 days: HR = 1.03 (0.86–1.23)
≤101 days: Reference
DRTI
















Not associated with OS (p = 0.387)
SRTI
≥71 days: HR = 1.001 (0.999–1.004)
40–70 days: HR = 1.004 (1.000–1.008)
<40 days: HR = 1.006 (0.994–1.017)
RTI
≥55 days: HR = 1.000 (0.998-1.002)







with oral cancer from




24–55.5 days: HR = 1.75 (p = 0.04)
127.5–420 days: HR = 1.55 (p = 0.09)
55.5–127.5 days: Reference
Abbreviations: SCC = Squamous Cell Carcinoma; TCRD = Taiwan Cancer Registry Database; DTI = Diagnosis-to-treatment interval; OS
= Overall Survival; OSCC = Oropharyngeal Squamous Cell Carcinoma; NCDB = National Cancer Data Base; HNC = Head and Neck
Cancer; NCR = Netherlands Cancer Registry; HNSCC = Head and Neck Squamous Cell Carcinoma; DSI = Diagnosis-to-surgery interval;
SRTI = Surgery-to-radiotherapy interval (initiation); RTI = Radiotherapy duration interval; TTP = Total Treatment Package (surgery to
radiotherapy end); DRTI = Diagnosis-to-radiotherapy end; TI = Total Interval (from first symptom awareness to the initiation of treatment).
Van Harten et al. [42] found that in The Netherlands longer waiting times to initiation
of treatment was significantly associated with worse OS in patients diagnosed with HNC.
However, when the variable was categorized (≤30 days vs. >30 days) no significant
differences in OS were observed (HR: 1.0 95%CI 0.94–1.07). Murphy et al. (US) [51]
Cancers 2021, 13, 1321 9 of 13
reported that a pre-treatment interval of 30 to 60 days had no impact on OS from HNC
but demonstrated that the mortality risk raised substantially after 67 days and with higher
time-intervals (61–90 days = HR: 1.13, 95% CI 1.08–1.19 and >90 days = HR: 1.29, 95%CI
1.21–1.38) (Table 2).
Regarding the radiation interval (time for the first to the last day of radiation), Fujiwara
et al. [38] found that in the US prolonged radiotherapy duration was significantly associated
with worse OS. Patients with 54 or more days of radiotherapy duration had a 5-year OS
rate of 40.5%, compared to the 52.4% in patients with 49 days or less of radiotherapy
duration (HR: 1.22, 95%CI 1.03–1.44). The authors discussed that may be due to the
rapid repopulation of tumor clones during treatment breaks [38]. Similarly, Ho et al. [52]
demonstrated no detriment to survival in the US if radiation was initiated within 40 days of
surgery. Mortality risk began to increase beyond this time point, plateauing at 70 days (HR:
1.14, 95%CI 1.01–1.28) with further postoperative “delays” not worsening the prognosis.
The radiation interval was also significantly associated with mortality risk from HNC
which increased continuously within each day of “delay” up to 55 days (HR: 1.25, 95%CI
1.11–1.41, reference ≤40 days). The pre-treatment interval had not prognostic value on
mortality from HNC after adjusted analyses.
Currently, only one study [53] has assessed the impact of the total time-interval on
mortality from oral cancer. The authors found a U-shaped association, where patients with
short time-intervals (24–55.5 days) and with long time-intervals (127.5–420 days) had a
higher mortality than those with medium time-intervals. Higher mortality rates in patients
with shorter time-intervals could be explained by confounding by severity and tumor
aggressiveness [53].
6. Discussion
It is well known that the prognosis of patients with oral cancer largely depends on
the stage of the disease at the time of diagnosis. The challenge, therefore, is to advance
the diagnosis to an earlier stage, which then would result in less morbidity and a better
prognosis [54]. Strategies for diagnosing oral cancer at an early stage include population
screening of high-risk groups, opportunistic screening by HCP and reducing the time-
intervals in diagnosis and treatment of oral cancer [55]. Since the patient interval is the
major contributor to the total time-interval, priority should be given to strategies aimed at
increasing public education and awareness of early signs and/or symptoms of HNC [13].
Education of the public and HCP on early cancer signs is part of the early detection
approach in many countries but there have been few investigations on the impact of
awareness campaigns on cancer outcomes [56]. A systematic review published in 2009,
found limited evidence regarding the effectiveness of educational interventions aimed
at increasing cancer knowledge and promoting early presentation at the individual and
community-level [57]. Moreover, research in this field regarding HNC awareness are scarce,
and the available evidence shows a modest short-term increase oral cancer knowledge
at the individual level after the delivery of written information [58–61]. Short-term mass
campaigns among the general population have shown inconsistent results with limited
effect at increasing oral cancer awareness [62–65] and some effectiveness at increasing oral
cancer screening among the high-risk population [63].
Furthermore, if educational/health interventions actually promote an early presenta-
tion and, therefore, the diagnosis at an earlier stage is still undetermined. In 2012, Scott
et al. [66] reported that a pilot theory-intervention in the UK had, in the short-term, a
small effect in reducing anticipated delay in seeking help for potentially malignant oral
symptoms (waiting time of more than 3 months before consulting a HCP) and a recent
trend analysis conducted in Northern Germany showed a slight increase in the proportion
of women diagnosed with oral cancer at stage I after the implementation of an awareness
campaign [67]. Although the scarcely evidence shows some positive impact on clinical and
patient’s outcomes, this is still a subject that needs further research before the assessment
of clinical implications.
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The introduction of a fast-track policy for urgent referral for suspected cancer (NICE
guidance for primary care) in the UK have shown some effectiveness in reducing the
diagnostic interval from several cancers since its implementation in 2005, including HNC
with a mean reduction of 21 days [68]. It is feasible that changes in policy and practice
may have increased awareness of early signs and symptoms in primary care physicians
leading to earlier referral to specialist or diagnostic investigation and, thus, reducing this
time-interval [68]. Although many other countries have developed and implemented
policies and clinical guidelines for the diagnosis and management of cancer, the impact
of such strategies on the diagnosis and treatment intervals and, subsequently, on cancer
outcomes have yet not been assessed and are still poorly understood.
The evidence regarding the impact of prolonged time intervals on prognosis and sur-
vival from oral cancer have not demonstrated a strong association between the patient and
diagnostic intervals and poorer survival from HNC. An explanation for the heterogeneous
findings could be that the relationship is rather influenced by the proliferative activity of
the tumor than by delays itself, which would explain why patients who experienced a short
diagnostic interval had a bad prognosis and patients who experienced a long diagnostic
interval elicit good prognosis [46]. Stage of the disease at diagnosis has been identified
as one of the major prognostic factors for survival from oral cancer and it seems to be
dependent of the patient and diagnostic interval [49], however, the proliferative activity
of the tumor is an independent factor that should be considered in future research on the
topic. On the other hand, an emerging body of evidence focused on the pre-treatment
and treatment intervals have shown that prolonged time-to-treatment initiation, partic-
ularly beyond 2 months, negatively impacts survival from HNC [12], which may also
be confounded by the proliferative activity of the tumor as it has not been considered
as an independent factor associated with prognosis and survival in previous research.
Also, postoperative radiotherapy within 4-6 weeks of surgery have shown no detriment
to survival [47,52] which is supported by the National Comprehensive Cancer Network
Guidelines that recommend the postoperative interval to be less than 6 weeks [69].
7. Conclusions
The patient interval is the major contributor to the total time-interval. Unawareness
of signs and/or symptoms, denial and lack of knowledge about oral cancer are the major
contributors to the process of seeking medical attention, so future research should be
focused at assessing the impact of educational awareness campaigns and also health
interventions such as opportunistic screening or screening of high-risk groups on cancer
outcomes, mainly, early presentation, diagnosis at an early stage and survival from HNC.
There is an emerging body of evidence supporting the impact of prolonged pre-treatment
and treatment intervals with poorer survival from HNC which needs to be further clarified
by high-quality synthesis of studies. Future research on the topic must also consider the
proliferative activity of the tumor when assessing the impact of time-intervals on survival
from oral cancer.
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